Revista de Odontologia da UNESP
https://revodontolunesp.com.br/journal/rou/article/588017ae7f8c9d0a098b4852
Revista de Odontologia da UNESP
Original Article

Utilização dos AINEs seletivos para COX-2 na quimioprevenção do câncer de cabeça e pescoço

The usage of COX-2 selective non-steroidal anti-inflammatory drugs in the Chemoprevention of head and neck cancer

Sousa, F.A.C.G.; Paradella, T.C.; Rocha, R.F.; Rosa, L.E.B.

Downloads: 0
Views: 372

Abstract

Por mais de uma década, vários estudos vêm sugerindo o envolvimento da COX-2 no processo de carcinogênese. Entretanto, se por um lado ainda muito pouco se sabe sobre a importância clínica desse fato, por outro torna-se cada vez mais evidente a eficácia dos AINEs seletivos para COX-2 tanto na prevenção quanto no tratamento de diversos tipos de câncer. Nesse contexto, o presente trabalho tem como objetivo realizar uma breve revisão a respeito da participação da COX-2 no tratamento de câncer de cabeça e pescoço, ressaltando a importância das drogas capazes de inibí-la na quimioprevenção da doença.

Keywords

Câncer de cabeça e pescoço, antiinflamatórios não esteroidais, ciclooxigenase, quimioprevenção

Resumo

Over decade, many studies have been suggesting the involvement of COX-2 in the carcinogenesis process. Little is known regarding the clinical importance of this factor. However, it becomes evident the effectiveness of COX-2 selective non-steroidal anti-inflammatory drugs to prevent and treat of various types of cancer. Within this context, the present study has the goal to briefly review the participation of COX-2 in both the head and neck cancer, highlighting the importance of COX-2 selective non-steroidal anti-inflammatory drugs in chemoprevention these diseases.

Palavras-chave

Head and neck cancer, COX-2 selective non-steroidal anti-inflammatory drugs, chemoprevention

References



1. Carvalho WA, Carvalho RDS, Rios-Santos F. Specific cyclooxygenase-2 inhibitor analgesics: therapeutic advances. Rev Bras Anestesiol. 2004; 4: 448-64.

2. Dainichi T, Ueda S, Isoda M, Koga T, Kinukawa N, Nose Y, et al. Chemical peeling with salicylic acid in polyethylene glycol vehicle suppresses skin tumour development in hairless mice. Br J Dermatol. 2003; 148: 906-12.

3. Dempke W, Rie C, Grothey A, Schmoll HJ. Cyclooxigenase- 2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol. 2001; 127: 411-7.

4. Erovic BM, Pelzmann M, Turhani D, Pammer J, Niederberger V, Neuchrist C, et al. Differential expression pattern of cyclooxygenase-1 and -2 in head and neck squamous cell carcinoma. Acta Otolaryngol. 2003; 123: 950-3.

5. Fu SL, Wu YL, Zhang YP, Qiao MM, Chen Y. Anticancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer. World J Gastroenterol. 2004; 10: 1971-4.

6. Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, et al. Celecoxib inhibits N-butyl-N-(4- hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 2000; 60: 5599-602.

7. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by Celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 2000; 60: 2101-3.

8. Hla T, Neison K. Human cyclooxigenase-2 cDNA. Proc Natl Acad Sci USA. 1992; 89: 7384-8.

9. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem. 2000; 275: 11397-403.

10. Koki AT, Leahy KM, Masferrer JL. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Investig Drugs. 1999; 8: 1623-38.

11. Kuo CL, Chi CW, Kiu TY. Modulation of apoptosis by berberina through inhibition of cyclooxygenase-2 and Mcl-1 expression in oral cancer cells. In Vivo. 2005; 19: 247-52.

12. Lee DW, Park SW, Park SY, Heo DS, Kim KH, Sung MW. Effects of p53 or p27 overexpression on cyclooxygenase- 2 gene expression in head and neck squamous cell carcinoma cell lines. Head Neck. 2004; 26: 706-15.

13. Lee DW, Sung MW, Park SW, Seong WJ, Roh JL, Park B, et al. Increased cycooxygenase-2 expression in human squamous cell carcinomas of the head and neck and inhibition of proliferation by nonsteroidal anti-inflammatory drugs. Anticancer Res. 2002; 22: 2089-96.

14. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999; 59: 4356-62.

15. Nakatsugi S, Ohta T, Kawamori T, Mutoh M, Tanigawa T, Watanabe K, et al. Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1- methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res. 2000; 91: 886-92.

16. Nathan CA, Leskov IL, Lin M, Abreo FW, Shi R, Hartman GH, et al. COX-2 expression in dysplasia of the head and neck: correlation com eIF4E. Cancer. 2001; 92: 1888-95.

17. Nishimura G, Yanoma S, Mizuno H, Kawakami K, Tsukuda M. A selective cycooxigenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head neck squamous carcinoma cells. Jpn J Cancer Res. 1999; 90: 1152-62.

18. Okajima E, Denda A, Ozono S, Takahama M, Akai H, Sasaki Y, et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl- N-(4-hydroxybutyl)nitrosamine. Cancer Res. 1998; 58: 3028-31.

19. Orengo IF, Gerguis J, Phillips R, Guevara A, Lewis AT, Black HS. Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model. Arch Dermatol. 2002; 138: 751-5.

20. Pentland AP, Schoggins JW, Scott GA, Khan KN, Han R. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis. 1999; 20: 1939-44.

21. Pruthi RS, Derksen JE, Moore D. A pilot study of use of the cyclooxygenase-2 inhibitor Celecoxib in recurrent cancer after definitive radiation therapy or radical prostatectomy. BJU Int. 2004; 93: 275-8.

22. Rioux N, Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res. 1998; 58: 5354-60.

23. Rozic JG, Chakraborty C, Lala PK. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer. 2001; 93: 497-506.

24. Shiotani H, Denda A, Yamamoto K, Kitayama W, Endoh T, Sasaki Y, et al. Increased expression of cyclooxigenase- 2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res. 2001; 61: 1451-6.

25. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Selective Inhibition of cyclooxigenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. 2000; 60: 5767-72.

26. Tang DW, Lin SC, Chang KW, Chi CW, Chang CS, Liu TY. Elevated expression of cyclooxygenase (COX)-2 in oral squamous cell carcinoma – evidence for COX-2 induction by areca quid ingredients in oral keratinocytes. J Oral Pathol Med. 2003; 32: 522-9.

27. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res. 1995; 44: 1-10.

28. Wang Z, Fuentes CF, Shapshay SM. Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. Laryngoscope 2002; 112: 839-43.

29. Yao R, Rioux N, Castonguay A, You M. Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal anti-inflammatory drugs’ chemopreventive efficacies in mouse lung tumorigenesis. Exp Lung Res. 2000; 26: 731-42.

30. Yip-Schineider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, et al. Cyclooxigenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis. 2000; 21: 139-46.
588017ae7f8c9d0a098b4852 rou Articles
Links & Downloads

Rev. odontol. UNESP

Share this page
Page Sections